Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder
Posted on17 Dec 2014
Comments0
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing’s disease[1] In the Phase... Read More